

WHAT IS CLAIMED IS:

1. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for treating a patient with late-onset asthma, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient.
2. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for treating a patient with asthma that falls within Severe Asthma Research Program (SARP) clinical cluster 3 or 5, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient.
3. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for reducing the annual exacerbation rate (AER) in a patient with late-onset asthma, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient, wherein the administration reduces the patient's AER.
4. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for reducing the AER in a patient with asthma that falls within SARP clinical cluster 3, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient, wherein the administration reduces the patient's AER.
5. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for reducing the AER in a patient with asthma that falls within SARP clinical cluster 5, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient, wherein the administration reduces the patient's AER.
6. The use of any one of claims 3-5, wherein the AER is reduced by at least 45% compared to a patient not administered the benralizumab or antigen-binding fragment thereof.

7. The use of claim 6, wherein the AER is reduced by at least 50% compared to a patient not administered the benralizumab or antigen-binding fragment thereof.
8. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for improving lung function in a patient with late-onset asthma, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient.
9. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for improving lung function in a patient with asthma that falls within SARP clinical cluster 3, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient.
10. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for improving lung function in a patient with asthma that falls within SARP clinical cluster 5, wherein a therapeutically effective amount of benralizumab or the antigen-binding fragment thereof is to be administered to said patient.
11. The use of any one of claim 8-10, wherein the improved lung function is measured by an increase in the patient's percent predicted forced expiratory volume in 1 second (FEV₁) compared to the patient's FEV₁ prior to the administration.
12. The use of claim 11, wherein the FEV₁ is pre-bronchodilator (BD) FEV₁.
13. The use of claim 12, wherein the pre-BD FEV₁ is increased by at least 6%.
14. The use of 12, wherein the pre-BD FEV₁ is increased by at least 14%.
15. The use of claim 11, wherein the FEV₁ is post-bronchodilator (BD) FEV₁.